Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Mayo Clinic to study theranostics technology

21 October 2026 · By · Wire by Fusion42

Published

21 October 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at beckersoncology.com →

◆ Verified

Fusion42 · 22 October 2026 · Fusion42 review

Mayo Clinic is participating in a clinical evaluation program for GE HealthCare’s new StarGuide GX SPECT/CT imaging system designed for theranostics, alongside institutions in Israel, France, and China. The system is cleared for sale in some EU countries but is pending FDA clearance.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You can position your cancer diagnostic startup to exploit demand ahead of FDA clearance by integrating this advanced imaging tech validated by Mayo Clinic. Competitors relying on older imaging approaches risk losing ground as theranostics imaging gains clinical credibility and adoption.

◆ Coverage

1 source · 21 Oct 2026

◆ Related on Wire

◆ Topics

Medtechtheranosticsmedical-imagingclinical-evaluationmayo-clinicge-healthcare